Paragon’s Portfolio Company Emalex Biosciences Announces Positive Topline Results from Phase 2b Clinical Study Evaluating Ecopipam for Pediatric Tourette Syndrome
Statistically significant, clinically meaningful results obtained on the primary and multiple secondary efficacy endpoints; ecopipam well tolerated in the study Chicago, Nov. 10, 2021 – Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company founded by Paragon Biosciences to develop treatments for central nervous system movement disorders and fluency disorders, today announced positive topline results from its [...]
Emalex Biosciences Recruiting People Who Stutter for Phase 2 Clinical Trial for Childhood-Onset Fluency Disorder
Current enrollment for stuttering study is at 75%; Nine U.S. Sites Nationwide Chicago, September 14, 2021 – Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company focused on developing treatments for central nervous system movement disorders and fluency disorders, is seeking people who stutter to complete its Phase 2 clinical trial enrollment for childhood-onset fluency disorder in adults, also [...]
Emalex Biosciences Announces Completion of Patient Enrollment in Phase 2b Clinical Trial Evaluating Ecopipam (EBS-101) for Pediatric Patients with Tourette Syndrome
Paragon Biosciences’ Portfolio Company Focuses on Areas with High Unmet Needs Chicago, June 22, 2021 – Emalex Biosciences, Inc. (“Emalex”), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system movement disorders and fluency disorders, announced today that its Phase 2b clinical trial evaluating the efficacy and safety of ecopipam (EBS-101) for the treatment of [...]
Sai Chavala, M.D., Receives ARVO Foundation Ludwig Von Sallmann Clinician-Scientist Award
Dr. Chavala is co-founder of CiRC Biosciences with Jeff Aronin, chairman and CEO of Paragon Biosciences Chicago, June 3, 2021—CiRC Biosciences, Inc., Co-Founder and Chief Scientific Officer Sai Chavala, M.D., has been awarded the 2021 Ludwig von Sallmann Clinician-Scientist Award from the Association for Research in Vision and Ophthalmology (ARVO) Foundation for Eye Research. Dr. Chavala was [...]
Emalex Biosciences Raises $35 Million in Series C Preferred Stock to Advance Tourette Syndrome and Stuttering Clinical Trials
Funding led by Paragon Biosciences, joined by Fidelity Management & Research Company LLC and Valor Equity Partners Chicago, March 23, 2021 – Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company founded to develop treatments for central nervous system movement disorders and fluency disorders, today announced $35 million in Series C Preferred Stock funding led by Paragon Biosciences. Fidelity [...]
CiRC Biosciences Announces Orphan Drug Designation for Treatment of Retinitis Pigmentosa (RP)
Cell Therapy Platform Seeks to Restore Vision for People with RP Chicago, March 10, 2021— CiRC Biosciences, Inc., a privately held cell therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for chemically induced photoreceptor-like cells (CiPCs) for the treatment of retinitis pigmentosa (RP). With an initial focus on [...]
